Clinical trials: STEMI - ST Elevation Myocardial Infarction
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
STEMI (ST Elevation MI)
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
The goal of this interventional study is to evaluate if the CoFI system can act as a platform for intracoronary infusion of therapeutic agents to treat and relieve microvascular injury in ST Elevation Acute Coronary Syndrome…
- Trial name
- REVITALISE (NCT06935383)
- Testing
- Therapeutic sequence, Diagnostic sequence
- Volunteers
- 250 people
- Sponsor
- CorFlow Therapeutics AG
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences
Acute Myocardial Infarction With ST Elevation
Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
The aim of the present study was to investigate the efficacy of ischemic postconditioning in acute myocardial infarction patients. The safety of patients enrolled in the study was ensured during the entire study.
- Trial name
- NCT04824716
- Testing
- Postconditioning, Percutaneous coronary intervention
- Where
- 3 sites in Hungary
- Volunteers
- 100 people
- Sponsor
- Peter Ferdinandy
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.
Coronary Stenosis, Acute Coronary Syndrome
Systemic, Pancoronary and Local Coronary Vulnerability
The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- VIP (NCT03606330)
- Testing
- Cardiac imaging tests, Venous blood sample collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
ST Elevation Myocardial Infarction
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI)…
- Trial name
- NCT03991143
- Testing
- ATH3G10
- Where
- Sweden
- Volunteers
- 82 people
- Sponsor
- Athera Biotechnologies AB
Myocardial Infarction
Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction
The primary objective of this study is to characterize the morphological patterns of high frequency QRS components (HFQRS) in patients with acute myocardial infarction (AMI), including STEMI and NSTEMI, compared to patients…
- Trial name
- NCT01150825
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- BSP Biological Signal Processing Ltd.